Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹53,068 Cr
Revenue (TTM)
₹6,722 Cr
Net Profit (TTM)
₹843 Cr
ROE
8.3 %
ROCE
10.2 %
P/E Ratio
62.9
P/B Ratio
10.5
Industry P/E
46.99
EV/EBITDA
30.8
Div. Yield
0.1 %
Debt to Equity
0.6
Book Value
₹93.7
EPS
₹15.6
Face value
2
Shares outstanding
539,856,582
CFO
₹5,406.87 Cr
EBITDA
₹8,501.77 Cr
Net Profit
₹3,977.62 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Laurus Labs
| -11.2 | -3.0 | -2.6 | 69.2 | 48.0 | 23.0 | -- |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Laurus Labs
| 80.0 | 39.2 | 14.6 | -30.4 | 52.5 | 379.5 | -6.1 |
|
BSE Mid Cap
| 1.1 | 25.8 | 45.5 | 1.4 | 39.2 | 19.9 | -3.0 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Laurus Labs
|
983.4 | 53,067.9 | 6,721.6 | 841.8 | 18.1 | 18.2 | 62.9 | 10.5 |
| 2,257.8 | 18,500.8 | 1,215.1 | 284.8 | 28.7 | 21.1 | 64.5 | 12.2 | |
| 2,186.3 | 61,701.8 | 16,468.1 | 1,065.0 | 23.2 | 26.6 | 57.9 | 6.2 | |
| 587.2 | 14,551.9 | 5,092.5 | 545.5 | 15.9 | 14.1 | 26.7 | 3.5 | |
| 856.6 | 13,645.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 31.5 | 2.1 | |
| 957.9 | 17,149.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11 | 2.0 | |
| 1,471.6 | 16,867.1 | 1,419.3 | 20.1 | 8.4 | 0.5 | 839.1 | 2.9 | |
| 143.1 | 19,028.2 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 419.9 | 16,903.3 | 3,720.2 | 352.1 | 13.7 | 8.2 | 48 | 3.6 | |
| 1,215.6 | 19,800.5 | 3,151.0 | -10.0 | 8.4 | 2.5 | 900 | 4.3 |
Laurus Labs: What hinders its growth?
3 min read•By Hemkesh Khattar
Companies falling short of cash
2 min read•By Rajan Gulati
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV),... antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India. Read more
Incorporated
2005
Chairman
Ravindranath Kancherla
Managing Director
--
Headquarters
Vishakhapatnam, Andhra Pradesh
Website
Looking for more details about Laurus Labs Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Laurus Labs Ltd is ₹983.40 (NSE) and ₹983.00 (BSE) as of 18-Mar-2026 IST. Laurus Labs Ltd has given a return of 48.03% in the last 3 years.
The P/E ratio of Laurus Labs Ltd is 62.93 times as on 18-Mar-2026, a 34 premium to its peers’ median range of 46.99 times.
The P/B ratio of Laurus Labs Ltd is 10.49 times as on 18-Mar-2026, a 247 premium to its peers’ median range of 3.02 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
92.37
|
7.44
|
|
2024
|
133.90
|
5.16
|
|
2023
|
20.12
|
3.92
|
|
2022
|
38.31
|
9.49
|
|
2021
|
19.75
|
7.49
|
The 52-week high and low of Laurus Labs Ltd are Rs 1,141.00 and Rs 517.65 as of 19-Mar-2026.
Laurus Labs Ltd has a market capitalisation of ₹ 53,068 Cr as on 18-Mar-2026. As per SEBI classification, it is a Mid Cap company.
Before investing in Laurus Labs Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹14.70
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.